186 related articles for article (PubMed ID: 27211612)
1. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.
Jones SA; Breen C; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Pan L; Qiu Y; Chung JK; Nair N; Haslett PAJ; Barbier AJ; Wijburg FA
Mol Genet Metab; 2016 Jul; 118(3):198-205. PubMed ID: 27211612
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
Wijburg FA; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Nestrasil I; Shapiro E; Jones SA; Alexanderian D
Mol Genet Metab; 2021 Dec; 134(4):317-322. PubMed ID: 34600820
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: A phase IIb randomized trial.
Wijburg FA; Whitley CB; Muenzer J; Gasperini S; Del Toro M; Muschol N; Cleary M; Sevin C; Shapiro E; Bhargava P; Kerr D; Alexanderian D
Mol Genet Metab; 2019 Feb; 126(2):121-130. PubMed ID: 30528227
[TBL] [Abstract][Full Text] [Related]
4. Whole Body and CNS Biodistribution of rhHNS in Cynomolgus Monkeys after Intrathecal Lumbar Administration: Treatment Implications for Patients with MPS IIIA.
Chung JK; Pan L; Palmieri K; Youssef AS; McCauley TG
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29194406
[TBL] [Abstract][Full Text] [Related]
5. A multicenter open-label extension study of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
Wijburg FA; Whitley CB; Muenzer J; Gasperini S; Del Toro M; Muschol N; Cleary M; Sevin C; Shapiro E; Alexanderian D
Mol Genet Metab; 2021; 134(1-2):175-181. PubMed ID: 34247932
[TBL] [Abstract][Full Text] [Related]
6. Final results of the phase 1/2, open-label clinical study of intravenous recombinant human N-acetyl-α-d-glucosaminidase (SBC-103) in children with mucopolysaccharidosis IIIB.
Whitley CB; Vijay S; Yao B; Pineda M; Parker GJM; Rojas-Caro S; Zhang X; Dai Y; Cinar A; Bubb G; Patki KC; Escolar ML
Mol Genet Metab; 2019 Feb; 126(2):131-138. PubMed ID: 30635159
[TBL] [Abstract][Full Text] [Related]
7. Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study.
Harmatz P; Muenzer J; Ezgü F; Dalén P; Huledal G; Lindqvist D; Gelius SS; Wikén M; Önnestam K; Bröijersén A
Mol Genet Metab; 2022 Aug; 136(4):249-259. PubMed ID: 35835061
[TBL] [Abstract][Full Text] [Related]
8. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516
[TBL] [Abstract][Full Text] [Related]
9. High dose genistein in Sanfilippo syndrome: A randomised controlled trial.
Ghosh A; Rust S; Langford-Smith K; Weisberg D; Canal M; Breen C; Hepburn M; Tylee K; Vaz FM; Vail A; Wijburg F; O'Leary C; Parker H; Wraith JE; Bigger BW; Jones SA
J Inherit Metab Dis; 2021 Sep; 44(5):1248-1262. PubMed ID: 34047372
[TBL] [Abstract][Full Text] [Related]
10. Robust LC-MS/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA.
Makower Å; Arnelöf E; Andersson T; Edlund PO; Gustavsson S; Janson J; Gelius SS; Tjernberg A
Bioanalysis; 2019 Aug; 11(15):1389-1403. PubMed ID: 31490106
[No Abstract] [Full Text] [Related]
11. A novel LC-MS/MS assay for heparan sulfate screening in the cerebrospinal fluid of mucopolysaccharidosis IIIA patients.
Naimy H; Powell KD; Moriarity JR; Wu J; McCauley TG; Haslett PA; Barbier AJ; Qiu Y
Bioanalysis; 2016 Feb; 8(4):285-95. PubMed ID: 26847798
[TBL] [Abstract][Full Text] [Related]
12. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-
Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF
Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673
[TBL] [Abstract][Full Text] [Related]
13. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
[TBL] [Abstract][Full Text] [Related]
14. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design.
Truxal KV; Fu H; McCarty DM; McNally KA; Kunkler KL; Zumberge NA; Martin L; Aylward SC; Alfano LN; Berry KM; Lowes LP; Corridore M; McKee C; McBride KL; Flanigan KM
Mol Genet Metab; 2016 Nov; 119(3):239-248. PubMed ID: 27590925
[TBL] [Abstract][Full Text] [Related]
15. Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA.
King B; Marshall NR; Hassiotis S; Trim PJ; Tucker J; Hattersley K; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM
J Inherit Metab Dis; 2017 May; 40(3):443-453. PubMed ID: 27832416
[TBL] [Abstract][Full Text] [Related]
16. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
[TBL] [Abstract][Full Text] [Related]
17. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.
Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ
Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain.
King B; Marshall N; Beard H; Hassiotis S; Trim PJ; Snel MF; Rozaklis T; Jolly RD; Hopwood JJ; Hemsley KM
J Inherit Metab Dis; 2015 Mar; 38(2):341-50. PubMed ID: 25421091
[TBL] [Abstract][Full Text] [Related]
19. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.
Hemsley KM; King B; Hopwood JJ
Mol Genet Metab; 2007 Mar; 90(3):313-28. PubMed ID: 17166757
[TBL] [Abstract][Full Text] [Related]
20. Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
Ellinwood NM; Valentine BN; Hess AS; Jens JK; Snella EM; Jamil M; Hostetter SJ; Jeffery ND; Smith JD; Millman ST; Parsons RL; Butt MT; Chandra S; Egeland MT; Assis AB; Nelvagal HR; Cooper JD; Nestrasil I; Mueller BA; Labounek R; Paulson A; Prill H; Liu XY; Zhou H; Lawrence R; Crawford BE; Grover A; Cherala G; Melton AC; Cherukuri A; Vuillemenot BR; Wait JCM; O'Neill CA; Pinkstaff J; Kovalchin J; Zanelli E; McCullagh E
J Pharmacol Exp Ther; 2022 Sep; 382(3):277-286. PubMed ID: 35717448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
